Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ:RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will participate in a fireside chat at the Piper Sandler 33rd Annual Healthcare Conference being held virtually November 29-December 2, 2021 and at the Evercore ISI 4th Annual Health CONx Virtual Conference being held virtually November 30-December 2, 2021.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Additional details can be found below:
Conference: Piper Sandler 33rd Annual Healthcare Conference
Date and Time: Prerecorded presentation will be available in advance beginning today, November 22, 2021, at 10:00 a.m. ET
Location: Webcast Link - or at the company's website (click here)
Conference: Evercore ISI 4th Annual Health CONx Virtual Conference
Date: Thursday, December 2, 2021
Time: 3:00 p.m. ET
Location: Webcast Link - or at the company's website (click here)
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Replay of the presentations will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
+1.646.876.5196
jtemperato@lifescicomms.com
Investor Contact:
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.